Estrogen receptor alpha and beta in health and disease

Min Jia; Karin Dahlman-Wright; Jan Åke Gustafsson

doi:10.1016/j.beem.2015.04.008

Estrogen receptor alpha and beta in health and disease

Min Jia, Karin Dahlman-Wright, Jan Åke Gustafsson

Houston Methodist

Research output: Contribution to journal › Review article › peer-review

396 Scopus citations

Abstract

Estrogen receptors alpha (ERα) and beta (ERβ) are transcription factors that are involved in the regulation of many complex physiological processes in humans. Abnormal ER signaling leads to development of a variety of diseases, such as cancer, metabolic and cardiovascular disease, neurodegeneration, inflammation, and osteoporosis. This review provides an overview and update on ERα and ERβ in health and disease with focus on their role in cancer and metabolic disease and in the context of recent years' success in providing genome wide data on ER function. Furthermore, potential clinical applications and challenges are also discussed.

Original language	English (US)
Pages (from-to)	557-568
Number of pages	12
Journal	Best Practice and Research: Clinical Endocrinology and Metabolism
Volume	29
Issue number	4
DOIs	https://doi.org/10.1016/j.beem.2015.04.008
State	Published - Aug 1 2015

Keywords

cancer
estrogen receptors
metabolic disease

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1016/j.beem.2015.04.008

Cite this

@article{1c5ac986b1de47a7b0039cedd937a973,

title = "Estrogen receptor alpha and beta in health and disease",

abstract = "Estrogen receptors alpha (ERα) and beta (ERβ) are transcription factors that are involved in the regulation of many complex physiological processes in humans. Abnormal ER signaling leads to development of a variety of diseases, such as cancer, metabolic and cardiovascular disease, neurodegeneration, inflammation, and osteoporosis. This review provides an overview and update on ERα and ERβ in health and disease with focus on their role in cancer and metabolic disease and in the context of recent years' success in providing genome wide data on ER function. Furthermore, potential clinical applications and challenges are also discussed.",

keywords = "cancer, estrogen receptors, metabolic disease",

author = "Min Jia and Karin Dahlman-Wright and Gustafsson, {Jan {\AA}ke}",

note = "Funding Information: Jan-{\AA}ke Gustafsson receives support from The Swedish Cancer Fund and the Robert A. Welch Foundation ( E-0004 ). Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "2015",

month = aug,

day = "1",

doi = "10.1016/j.beem.2015.04.008",

language = "English (US)",

volume = "29",

pages = "557--568",

journal = "Best Practice and Research: Clinical Endocrinology and Metabolism",

issn = "1521-690X",

publisher = "Bailliere Tindall Ltd",

number = "4",

}

TY - JOUR

T1 - Estrogen receptor alpha and beta in health and disease

AU - Jia, Min

AU - Dahlman-Wright, Karin

AU - Gustafsson, Jan Åke

N1 - Funding Information: Jan-Åke Gustafsson receives support from The Swedish Cancer Fund and the Robert A. Welch Foundation ( E-0004 ). Publisher Copyright: © 2015 Elsevier Ltd. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Estrogen receptors alpha (ERα) and beta (ERβ) are transcription factors that are involved in the regulation of many complex physiological processes in humans. Abnormal ER signaling leads to development of a variety of diseases, such as cancer, metabolic and cardiovascular disease, neurodegeneration, inflammation, and osteoporosis. This review provides an overview and update on ERα and ERβ in health and disease with focus on their role in cancer and metabolic disease and in the context of recent years' success in providing genome wide data on ER function. Furthermore, potential clinical applications and challenges are also discussed.

AB - Estrogen receptors alpha (ERα) and beta (ERβ) are transcription factors that are involved in the regulation of many complex physiological processes in humans. Abnormal ER signaling leads to development of a variety of diseases, such as cancer, metabolic and cardiovascular disease, neurodegeneration, inflammation, and osteoporosis. This review provides an overview and update on ERα and ERβ in health and disease with focus on their role in cancer and metabolic disease and in the context of recent years' success in providing genome wide data on ER function. Furthermore, potential clinical applications and challenges are also discussed.

KW - cancer

KW - estrogen receptors

KW - metabolic disease

UR - http://www.scopus.com/inward/record.url?scp=84940436309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940436309&partnerID=8YFLogxK

U2 - 10.1016/j.beem.2015.04.008

DO - 10.1016/j.beem.2015.04.008

M3 - Review article

C2 - 26303083

AN - SCOPUS:84940436309

SN - 1521-690X

VL - 29

SP - 557

EP - 568

JO - Best Practice and Research: Clinical Endocrinology and Metabolism

JF - Best Practice and Research: Clinical Endocrinology and Metabolism

IS - 4

ER -

Estrogen receptor alpha and beta in health and disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this